Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to 5735.95%.

  • Bioadaptives' EBITDA Margin changed N/A to 5735.95% in Q3 2025 from the same period last year, while for Sep 2025 it was 14410.84%, marking a year-over-year decrease of 127674800.0%. This contributed to the annual value of 4752.47% for FY2024, which is 39510600.0% down from last year.
  • Latest data reveals that Bioadaptives reported EBITDA Margin of 5735.95% as of Q3 2025.
  • Bioadaptives' EBITDA Margin's 5-year high stood at 415.47% during Q1 2024, with a 5-year trough of 13774.52% in Q2 2024.
  • For the 5-year period, Bioadaptives' EBITDA Margin averaged around 3514.14%, with its median value being 2770.7% (2022).
  • Per our database at Business Quant, Bioadaptives' EBITDA Margin crashed by -113825100bps in 2024 and then soared by 51004300bps in 2025.
  • Bioadaptives' EBITDA Margin (Quarter) stood at 4615.27% in 2021, then soared by 85bps to 685.29% in 2022, then fell by -25bps to 857.99% in 2023, then plummeted by -1505bps to 13774.52% in 2024, then surged by 58bps to 5735.95% in 2025.
  • Its last three reported values are 5735.95% in Q3 2025, 8674.09% for Q2 2025, and 13774.52% during Q2 2024.